Back to Industry News
General
EQL Pharma Issues Profit Warning After Delivery Delays: Dagens industri
Summary generated with AI, editor-reviewed
Heartspace News Desk
•Source: Dagens industri
Photo by Erik Mclean on Unsplash
Stay updated on stories like this
Key takeaways
- Kameo, a financing company, promotes itself as a streamlined and adaptable alternative to traditional banks for real estate project funding in a sponsored article
- General Manager Fredrik Källgren reports that Kameo has facilitated 8 billion SEK in loans for Scandinavian property projects since its 2016 inception
- Kameo differentiates itself by financing projects starting at 10 million SEK and offering financing plans within weeks, a significantly shorter timeframe compared to the typical 6–12 month approval process at traditional banks
Kameo, a financing company, promotes itself as a streamlined and adaptable alternative to traditional banks for real estate project funding in a sponsored article. General Manager Fredrik Källgren reports that Kameo has facilitated 8 billion SEK in loans for Scandinavian property projects since its 2016 inception.
Kameo differentiates itself by financing projects starting at 10 million SEK and offering financing plans within weeks, a significantly shorter timeframe compared to the typical 6–12 month approval process at traditional banks. Furthermore, Kameo provides financing for residential projects without requiring pre-sold units. Funding is derived from Kameo's internal credit fund, institutional partnerships, and its investor platform network.
Owned by ABG Sundal Collier and Incore Invest, Kameo reports a low credit loss rate of 0.1 percent on completed loans. The article explicitly discloses its collaborative production with Kameo and its independent status from Dagens industri.
Related Topics
EQL Pharmaprofit warningdelivery delayspharmaceuticalsfinancial performance
Never miss stories like this